Ximelagatran v placebo for secondary prevention of venous thromboembolism (VTE) at 18 months*

OutcomesXimelagatranPlaceboRRR (95% CI)NNT (CI)
*Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated using Cox proportional hazards ratio in article.
VTE2.8%12.6%83% (69 to 90)10 (9 to 12)
All cause mortality1.1%1.4%17% (−143 to 72)Not significant
Major bleeding1.1%1.3%16% (−65 to 273)Not significant
Major and minor bleeding23.9%21.0%16% (−6 to 44)Not significant